Facebook
Twitter
LinkedIn
Forward
Contemporary Management of MIBC and Beyond (2024)
COMPLIMENTARY CME LIVE VIRTUAL COURSES!
Join the AUA for Contemporary Management of MIBC and Beyond: Expert Guidance for Urologists and APPs, featuring two dynamic programs – one tailored specifically for Urologists and another for Advanced Practice Providers. Each course will showcase an expert multidisciplinary panel ready to dive into an engaging discussion on the latest breakthroughs and strategies in MIBC management. Don’t miss this chance to elevate your expertise in this critical field. Register today!
For more information on and to register for Contemporary Management of MIBC and Beyond: Expert Guidance for Urologists, click here.
For more information on and to register for Contemporary Management of MIBC and Beyond: Expert Guidance for APPs, click here.
Acknowledgements
Support provided by an independent educational grant from:
- Astellas and Pfizer, Inc.
Target Audience
- Urologists
- APPs
Learning Objectives
Contemporary Management of MIBC and Beyond: Expert Guidance for Urologists
After participating in this CME activity, participants will be able to:
- Describe the multimodal treatment approach for MIBC, including surgery, radiation therapy, and chemotherapy.
- Analyze the role of neoadjuvant and adjuvant therapies, including chemotherapy, immunotherapy, and antibody drug conjugates, in improving patient outcomes.
- Utilize knowledge of checkpoint inhibitors and antibody drug conjugates with their mechanisms of action to interpret the role of immunotherapy in the treatment of metastatic urothelial carcinoma.
- Examine ongoing clinical trials and emerging treatments that are shaping the future of metastatic urothelial carcinoma management.
- Employ appropriate patient and family education strategies regarding MIBC and metastatic urothelial carcinoma, treatment options, and expected outcomes.
Contemporary Management of MIBC and Beyond: Expert Guidance for APPs
After participating in this CME activity, participants will be able to:
- Explain the diagnostic criteria and staging systems for MIBC, emphasizing the importance of accurate staging in treatment planning.
- Prepare for the common side effects associated with the treatment of MIBC and metastatic urothelial carcinoma that may occur.
- Employ supportive care strategies in the overall management plan, including palliative care and psychosocial support.
- Assist with the preparation of long-term follow-up and survivorship care plans for patients, including monitoring for recurrence and managing long-term side effects.